Pre-Clinical Assessment of Phyllanthus Amarus Leaf Fraction on Arsenate Treated Hepato-Renal and Pancreatic Cells
Main Article Content
Abstract
With increasing anthropogenic activities, man is faced with carcinogenic substances like arsenate, which according to the Agency for Toxic Substances and Diseases Registry, is top on the list of twenty most toxic substances of public health concern. Therefore, this research investigated the effects of P. amarus leaf fraction on arsenate toxicity on key cell lines, with focus on addressing the challenge of arsenic poison in food and the environment. Various assays such as free radical scavenging assays and in-vitro cell lines assays on Human hepatic (HepG2), Kidney epithelial (LLCPK1), fibroblast and clonal pancreatic cells were employed using crude and pure fractions of the leaf. Data obtained were subjected to analytical tools such as SPSS, and Mnova software. From five solvent extracts screened, ethyl acetate extract had strongest antioxidant activity against in-vitro radicals. In-vivo LD50 of sub-acute toxicity on Wistar rats is 707.11mg/Kg. The cell line study revealed that 10μg/mL and above of crude leaf fraction protected pancreatic cells from cytotoxic effect of sodium arsenate (about 33% cells are viable against 50mg/mL arsenate), while on normal cells, 1.0-100μg/mL of the fraction showed improved cell viability. The fraction is less toxic on kidney epithelial cells and no effect on kidney fibroblast compared to Doxorubicin drug. Moreso, the fraction activated Pregnane X Receptor (PXR) which is responsible for CYPs mRNA genes expression for enzymes involve in xenobiotic metabolism, in concentration-dependent manner. Pure compounds isolated also showed same activation on PXR. In Conclusion, P. amarus leaf fraction act as ameliorative agent against arsenic toxicity as demonstrated through rejuvenation of cell growth due to its polyphenols, known for their membrane stabilizing activity by inhibiting ROS. It also acts as molecular ligand that activates PXR receptor. Although, it contains niranthin and cubebin dimethyl ether with same inhibitory potential as Ketoconazole which has been verified to have side effects.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Bae, J.Y., Avula, B., Wang, Y.H., Wang, M., Ali, Z., Alvaro, M.V. and Khan, I.A., 2019. Development and validation of a UHPLC-PDA-MS method for the quantitative analysis of anthraquinones in Bulbinenatalensis extracts and dietary supplements. Planta Medical, 86. 144–150.
II. Islam, H., Vamshi, M., Manal, A., Olivia, R.D., Ji-Yeong, B., Bharathi, A., Bill, J.G., Amar, G. C., Ikhlas, A.K and Shabana, I.K., 2021. Modulation of CYP3A4 and CYP2C9 activity by Bulbinenatalensisand its constituents: An assessment of HDI risk of B. natalensiscontaining supplements. Journal of Phytomed, (81), 153416. Elsevier.www.elsevier.com/locate/phymed.
III. John, O., Fatoki, Gbadebo, E., Adeleke, 2019. Time–Course of sodium arsenate induced hepatotoxicity and nephrotoxicity in male wistar rats. Journal of Natural Sci. Research, 10:71-76. doi: 10.7176/JNSR.
IV. Liu, Y., Zheng, B.H., Fu, Q., Meng, W and Wang, Y.Y., 2009. Risk assessment and management of arsenic in source water in China. Journal of Hazard mater, 170.729-734.
V. Lorke, D., 1983. A new approach to practical acute toxicity testing. Archive Toxi. 54(4), 275- 287.
VI. Mohammed, A.H and Idris, A.M., 2018. An overview of the hepatoprotective potentials of phyllanthus amarus. Journal of Pharmacognosy and Phytochem. 7(2), 2777-2782.
VII. Pius, S. F., Vamshi, K. M., Olivia, R. D., Nosa, O. E., Larry, A. W and Shabana, I. K., 2017. Modulation of cytochrome P450, P-glycoprotein and pregnane X receptor by selected antimalarial herbs—Implication for herb-drug interaction. Molecules, 2:2049. 1-12.
VIII. Shimizu, H., 2010. What's new in blistering diseases. The Journal of derma. 37(3), 193.
IX. Sprouse, A.A and Van-Breemen, R.B., 2016. Pharmacokinetic interactions between drugs and botanical dietary supplements. Drug Metabolism Disposition, 44. 162–171.
X. Sylvester, C. I and Arun, L.S., 2015. Level of arsenic in potable water sources in Nigeria and their potential health impacts: A review. Journal of Environmental Treatment Tech. 3(1), 15-24.
XI. US-FDA guideline, 2017. Clinical drug interaction studies-study design, data analysis, and clinical implications guidance for industry. http://www.fda. Gov/Drugs/Guidance Compliance Regulatory Information/Guidances/default. Htm.
XII. Van de Loosdrecht, A.A., Beelen, R.H., Ossenkoppele, G.J., Broekhoven and M.G., Langenhuijsen, M.M., 1994. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. Journal of Immun. Methods, 174(1-2), 311-20. doi: 10.1016/0022-1759(94)90034-5. PMID: 8083535.
XIII. World Health Organization, 2000. Arsenic. Regional office for Europe, Copenhagen, Denmark. Quality Guidelines 2nd ed. Chapter 6. pp. 1-14.
XIV. Yong-Chul J., Yashoda, S and Hwidong, K., 2016. Source, distribution, toxicity and remediation of arsenic in the environment – A Review. International Journal of Applied Environmental Sci. 11.559-581. ISSN 0973-6077.